MicroRNA‑335 inhibits bladder cancer cell growth and migration by targeting mitogen‑activated protein kinase 1

Wang,Xiaolin; Wu,Guang; Cao,Guangxin; Chen,Xiaohong; Huang,Jian; Jiang,Xiaohui; Hou,Jianquan

doi:10.3892/mmr.2016.5448

MicroRNA‑335 inhibits bladder cancer cell growth and migration by targeting mitogen‑activated protein kinase 1

Authors:
- Xiaolin Wang
- Guang Wu
- Guangxin Cao
- Xiaohong Chen
- Jian Huang
- Xiaohui Jiang
- Jianquan Hou
View Affiliations

Affiliations: Department of Urology, Nantong Tumor Hospital, Nantong, Jiangsu 226361, P.R. China, Department of Urology, The First Hospital of Wujiang, Suzhou, Jiangsu 215200, P.R. China, Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China
Published online on: June 27, 2016 https://doi.org/10.3892/mmr.2016.5448
Pages: 1765-1770

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The abnormal expression of microRNAs (miRs) as oncogenes or tumor‑suppressor genes has been widely investigated in various tumor types. However, the roles of miR‑335 in bladder cancer cells have remained elusive. The aim of the present study was to assess the expression of miR‑335 in bladder cancer as well as the effects of miR‑335 on bladder cancer cell proliferation, metastasis and apoptosis. PCR and western blot analyses revealed that miR‑335 was significantly downregulated in bladder cancer tissues, and low levels of miR‑335 were associated with more aggressive phenotypes of bladder cancer. Overexpression of miR‑335 in T24 cells inhibited cell proliferation and induced apoptosis as indicated by an MTT assay and flow cytometric analysis, respectively. Furthermore, overexpression of miR‑335 significantly suppressed cell migration, as indicated by a Transwell assay. The expression of mitogen‑activated protein kinase (MAPK)1 was decreased after overexpression of miR‑335, indicating that MAPK1 may be a target gene of miR‑335. In addition, silencing of MAPK1 inhibited the proliferation and migration of bladder cancer cells. In conclusion, the results of the present study demonstrated that miR‑335 was significantly downregulated in bladder cancer, and may act as a tumor suppressor through repression of MAPK1.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–13. 2013. View Article : Google Scholar : PubMed/NCBI
2	von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A and Arning M: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 23:4602–4608. 2005. View Article : Google Scholar : PubMed/NCBI
3	Shirodkar SP and Lokeshwar VB: Potential new urinary markers in the early detection of bladder cancer. Curr Opin Urol. 19:488–493. 2009. View Article : Google Scholar : PubMed/NCBI
4	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
5	Chen CZ, Li L, Lodish HF and Bartel DP: MicroRNAs modulate hematopoietic lineage differentiation. Science. 303:83–86. 2004. View Article : Google Scholar
6	Zhao Y, Samal E and Srivastava D: Serum response factor regulates a muscle specific microRNA that targets Hand2 during cardiogenesis. Nature. 436:214–220. 2005. View Article : Google Scholar : PubMed/NCBI
7	Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, et al: MiR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA. 102:13944–13949. 2005. View Article : Google Scholar : PubMed/NCBI
8	Sethi S, Ali S, Philip PA and Sarkar FH: Clinical advances in molecular biomarkers for cancer diagnosis and therapy. Int J Mol Sci. 14:14771–14784. 2013. View Article : Google Scholar : PubMed/NCBI
9	Ling H, Fabbri M and Calin GA: MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov. 12:847–865. 2013. View Article : Google Scholar : PubMed/NCBI
10	Zhu Z, Xu T, Wang L, Wang X, Zhong S, Xu C and Shen Z: MicroRNA-145 directly targets the insulin-like growth factor receptor I in human bladder cancer cells. FEBS Lett. 588:3180–3185. 2014. View Article : Google Scholar : PubMed/NCBI
11	Feng Y, Liu J, Kang Y, He Y, Liang B, Yang P and Yu Z: MiR-19a acts as an oncogenic microRNA and is up-regulated in bladder cancer. J Exp Clin Cancer Res. 33:672014. View Article : Google Scholar : PubMed/NCBI
12	Lei Y, Hu X, Li B, Peng M, Tong S, Zu X, Wang Z, Qi L and Chen M: MiR-150 modulates cisplatin chemosensitivity and invasiveness of muscle-invasive bladder cancer cells via targeting PDCD4 in vitro. Med Sci Monit. 20:1850–1857. 2014. View Article : Google Scholar : PubMed/NCBI
13	Inoguchi S, Seki N, Chiyomaru T, Ishihara T, Matsushita R, Mataki H, Itesako T, Tatarano S, Yoshino H, Goto Y, et al: Tumour-suppressive microRNA-24–1 inhibits cancer cell proliferation through targeting FOXM1 in bladder cancer. FEBS Lett. 588:3170–3179. 2014. View Article : Google Scholar : PubMed/NCBI
14	Wang X, Wu J, Lin Y, Zhu Y, Xu X, Liang Z, Li S, Hu Z, Zheng X and Xie L: MicroRNA-320c inhibits tumorous behaviors of bladder cancer by targeting Cyclin-dependent kinase 6. J Exp Clin Cancer Res. 33:692014. View Article : Google Scholar : PubMed/NCBI
15	Shi L, Jiang D, Sun G, Wan Y, Zhang S, Zeng Y, Pan T and Wang Z: miR-335 promotes cell proliferation by directly targeting Rb1 in meningiomas. J Neurooncol. 110:155–162. 2012. View Article : Google Scholar : PubMed/NCBI
16	Xu Y, Zhao F, Wang Z, Song Y, Luo Y, Zhang X, Jiang L, Sun Z, Miao Z and Xu H: MicroRNA-335 acts as a metastasis suppressor in gastric cancer by targeting Bcl-w and specificity protein 1. Oncogene. 31:1398–1407. 2012. View Article : Google Scholar :
17	Yan J, Jiang N, Huang G, Tay JL, Lin B, Bi C, Koh GS, Li Z, Tan J, Chung TH, et al: Deregulated MIR335 that targets MAPK1 is implicated in poor outcome of paediatric acute lymphoblastic leukaemia. Br J Haematol. 163:93–103. 2013. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCt method. Methods. 25:402–408. 2001. View Article : Google Scholar
19	Murali R, Chandramohan R, Möller I, Scholz SL, Berger M, Huberman K, Viale A, Pirun M, Socci ND, Bouvier N, et al: Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway. Oncotarget. 6:36041–36052. 2015.PubMed/NCBI
20	Esquela-Kerscher A and Slack FJ: Oncomirs- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006. View Article : Google Scholar : PubMed/NCBI
21	Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T and Visakorpi T: MicroRNA in prostate, bladder, and kidney cancer: A systematic review. Eur Urol. 59:671–681. 2011. View Article : Google Scholar : PubMed/NCBI
22	Tavazoie SF, Alarcón C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL and Massagué J: Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 451:147–152. 2008. View Article : Google Scholar : PubMed/NCBI
23	Fu Q, Liu X, Liu Y, Yang J, Lv G and Dong S: MicroRNA-335 and -543 suppress bone metastasis in prostate cancer via targeting endothelial nitric oxide synthase. Int J Mol Med. 36:1417–1425. 2015.PubMed/NCBI
24	Yan Z, Xiong Y, Xu W, Gao J, Cheng Y, Wang Z, Chen F and Zheng G: Identification of hsa-miR-335 as a prognostic signature in gastric cancer. PLoS One. 7:e400372012. View Article : Google Scholar : PubMed/NCBI
25	Kim EK and Choi EJ: Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta. 1802:396–405. 2010. View Article : Google Scholar : PubMed/NCBI
26	Kamiyama M, Naguro I and Ichijo H: In vivo gene manipulation reveals the impact of stress-responsive MAPK pathways on tumor progression. Cancer Sci. 106:785–796. 2015. View Article : Google Scholar : PubMed/NCBI